R&D JP Morgan 2024 – Xavier Duportet There were plenty of gene therapy companies around at JP Morgan 2024, and more than a few companies focused on the microbiome.
News Vedanta scores $106.5m to take microbiome drug into ph3 In the face of a challenging biotech financing environment, Vedanta Bio has ra
News FDA accepts review of SeresTx BLA for oral microbiome therap... The FDA has accepted for review Seres Therapeutics’ Biologics License Application (BLA) for SER-109, an investigational oral
Events Partner Content 6th Microbiome Movement - Drug Development Summit Europe New generation of microbiome-targeted therapeutics
News Nestle gets closer to Seres, pledging $525m for microbiome C... Swiss food giant Nestle has firmed up its five-year-old alliance with US microbiome specialist Seres, paying $175 million upfront for North American co-marketing rights to its lead drug for
Events Partner Content 6th Microbiome Movement - Drug Development Summit Discover the Next Generation of Microbiome Therapeutics
News Italy leads the way on child genetic disease diagnosis A scheme to hasten the diagnosis of children with genetic disorders is achieving strong results and could be a template for national health systems.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
